Clinical Trial - ARCADE Study in Dup15q Syndrome

The ARCADE trial is a Phase 2 multi-center, open-label, pilot study designed to evaluate the treatment of OV935 in pediatric patients with epileptic seizures associated Dup15q syndrome. The first patients have already been enrolled into ARCADE.
There are now 3 sites opening and 13 spots remaining in the trial!  
 
Ovid is recruiting dupers 2-17 with at least 3 seizures a month and are on anti-epileptic medications that are not giving seizure freedom.
 
The medication is in pill form and given twice a day during the trial.   
 
If a member of your community feels like this clinical trial might be right for them, they should contact one of the study clinics below to schedule a screening
 
The site coordinators can answer any questions about logistics
 
If there is ever any delay or questions that pop up, the community can always email us at: clinical@ovidrx.com and somebody from the team will get back to them within 24 hours.
 
ARCADE STUDY SITE AND CONTACT LIST:
  1. Minnesota Epilepsy Group: Sarah Ellis
Phone: 651-241-5075                               
 
  1. Mass General Hospital: Rachelle Bookman                                
Phone: 617-643-4212                                  
Email: rbookman@mgh.harvard.edu                                           
 
  1. Columbia: Wendy Chung
Phone 212-851-5313
 
  1. Center for Rare Disease (Atlanta): Ebun Dada
Phone: 617-984-9091
 
  1. UCLA: Fadiya Chowdhury
Phone: 310.206.3595
 
  1. Colorado: Janine Schenborn
Phone: (720) 777-4788